Rona Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Rona Therapeutics's estimated annual revenue is currently $2.8M per year.
- Rona Therapeutics's estimated revenue per employee is $155,000
- Rona Therapeutics's total funding is $93M.
Employee Data
- Rona Therapeutics has 18 Employees.
- Rona Therapeutics grew their employee count by 20% last year.
Rona Therapeutics's People
| Name | Title | Email/Phone |
|---|
Rona Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $1.4M | 9 | 80% | N/A | N/A |
#3 | $3.1M | 20 | -5% | $200M | N/A |
#4 | $8.7M | 56 | 2% | $146M | N/A |
#5 | $4.2M | 27 | -13% | $133M | N/A |
#6 | $0.9M | 6 | -14% | N/A | N/A |
#7 | $0.9M | 6 | 20% | N/A | N/A |
#8 | $0.8M | 5 | 25% | N/A | N/A |
#9 | $2.8M | 18 | 20% | $93M | N/A |
#10 | $1.4M | 9 | 29% | N/A | N/A |
What Is Rona Therapeutics?
Rona Therapeutics is a pioneering nucleic acid therapeutics company to discover, develop and deliver transformative modular RNA medicines to treat patients globally.\n\nRona Therapeutics is a global leader in nucleic acid innovative drug platform company, specializing in the treatment of metabolic diseases and neurological diseases. Rona Therapeutics is always committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases, obesity, and MASH. In addition, Rona Therapeutics is unlocking potential of extra-hepatic delivery for neurological disorders and adipose/muscle delivery for various metabolic syndromes.
keywords:N/A
$93M
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in shanghai
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.5M | 18 | 0% | N/A |
#2 | $2.5M | 18 | 0% | N/A |
#3 | $5.2M | 19 | 6% | N/A |
#4 | $3.1M | 19 | -14% | N/A |
#5 | $3.2M | 20 | 43% | N/A |